Liverpool Skylilne

Pharmacy and Biomolecular Sciences

Dr Andrew Evans

Dr Andrew Evans

Telephone: 0151 231 2145


Journal Articles

Guetchueng ST, Nahar L, Ritchie KJ, Ismail FMD, Wansi JD, Evans A, Sarker SD. 2017. Kaurane Diterpenes from the Fruits of Zanthoxylum leprieurii (Rutaceae) RECORDS OF NATURAL PRODUCTS, 11 :304-309 >Link

Tahsin T, Wansi JD, Al-Groshi A, Evans A, Nahar L, Martin C, Sarker SD. 2017. Cytotoxic Properties of the Stem Bark of Citrus reticulata Blanco (Rutaceae) PHYTOTHERAPY RESEARCH, 31 :1215-1219 >DOI >Link

Khan KM, Nahar L, Al-Groshi A, Zavoianu AG, Evans A, Dempster NM, Wansi JD, Ismail FMD, Mannan A, Sarker SD. 2016. Cytotoxicity of the Roots of Trillium govanianum Against Breast (MCF7), Liver (HepG2), Lung (A549) and Urinary Bladder (EJ138) Carcinoma Cells PHYTOTHERAPY RESEARCH, 30 :1716-1720 >DOI >Link

Sharma S, Evans A, Hemers E. 2016. Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1. Cell Tissue Res, :357-366 >DOI >Link

Bloch KM, Evans A, Lock EA. 2015. Aristolochic acids - Induced transcriptomic responses in rat renal proximal tubule cells in vitro. Genomics data, 5 :254-256

Bloch KM, Yaqoob N, Sharma S, Evans A, Aschauer L, Radford R, Jennings P, Ryan MP, Van Delft JHM, Lock EA. 2015. Transcriptomic alterations induced by Monuron in rat and human renal proximal tubule cells in vitro and comparison to rat renal-cortex in vivo TOXICOLOGY RESEARCH, 4 :423-431 >DOI >Link

Pujol-Gimenez J, de Heredia FP, Angel Idoate M, Airley R, Pilar Lostao M, Evans AR. 2015. Could GLUT12 be a Potential Therapeutic Target in Cancer Treatment? A Preliminary Report JOURNAL OF CANCER, 6 :139-143 >DOI >Link

Yaqoob N, Evans A, Foster JR, Lock EA. 2014. Trichloroethylene and trichloroethanol-induced formic aciduria and renal injury in male F-344 rats following 12 weeks exposure TOXICOLOGY, 323 :70-77 >DOI >Link

Airley RE, McHugh P, Evans AR, Harris B, Winchester L, Buffa FM, Al-Tameemi W, Leek R, Harris AL. 2014. Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression. Br J Cancer, 110 :715-723 >DOI >Link

Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A, Somavarapu S, Hutcheon GA, Saleem IY. 2013. Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers INTERNATIONAL JOURNAL OF PHARMACEUTICS, 441 :611-619 >DOI >Link

Yaqoob N, Evans AR, Lock EA. 2013. Trichloroethylene-induced formic aciduria: effect of dose, sex and strain of rat. Toxicology,

Evans AR, Airley R. 2012. How the science of personalized medicines will change the clinical management of patients in the pharmacy Future Medicinal Chemistry, 4 :2023-2026

Bloch KM, Yaqoob N, Evans A, Radford R, Jennings P, Boei JWA, McMorrow T, Slattery C, Ryan MP, Gmuender H, van Delft JHM, Lock EA. 2012. Detection of genotoxic and non-genotoxic renal carcinogens in vitro in NRK-52E cells using a transcriptomics approach. (2012). 1 :211-219

Airley R, Evans A, Mobasheri A, Hewitt SM. 2010. Glucose transporter Glut-1 is detectable in pen-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER, 192 :133-138 >DOI >Link

Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung Y-L, Phillips R, Stubbs M, Griffiths J, Airley R. 2008. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies (2008). Cancer Chemotherapy and Pharmacology, :377-393

Olidimeji B, Lerston S, Evans A, Estlin E, Airley R. 2005. Bone marrow hypoxia as a target in acute lymphoblastic leukaemia: toxicity assays using the bioreductive cytotoxic agent tirapazamine JOURNAL OF PHARMACY AND PHARMACOLOGY, 57 :S77-S77 >Link

Lonergan S, Haddad N, Evans A, Airley R. 2005. Ascorbic acid toxicity in tumours: role of facilitative glucose transporter Glut-1 and hypoxia JOURNAL OF PHARMACY AND PHARMACOLOGY, 57 :S77-S77 >Link

Hodgson G, Evans A, Airley R. 2005. Deregulated glucose transport as a target for anticancer drug development: use of a Glut-1 over-expressing colon carcinoma cell line to screen tyrosine kinase inhibitors for Glut-1-dependent toxicity JOURNAL OF PHARMACY AND PHARMACOLOGY, 57 :S76-S76 >Link

Airley RE, Phillips RM, Evans AE, Double J, Burger AM, Feibig HH, West CML, Stratford IJ. 2005. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int J Oncol, 26 :1477-1484 >Link

Khan KM, Nahar L, Evans A, Ismail FMD, Dempster N, Al-Groshi A, Zazoianu AG, Wansi JD, Sarker SD. Evaluation of cytotoxicity of Trillium govanianum (Melanthiaceae) Phytotherapy Research,

Conference Publication (journal proceedings)

Evans AR, Sharma S, Hemers, E . 2016. The role of High-Mobility Group Box 1 protein in mesenchymal-epithelial signalling in the tumour microenvironment. European journal of cancer, EACR 24th biennial conference 61 :S78-S78

Sheperd S, Chapman L, Day S, McHugh P, Evans AR, Airley R. 2014. The development of drug sensitivity biomarkers for personalized cancer chemotherapy

Bloch KM, Evans A, van Delft J, Lock EA. 2011. The effect of four non-genotoxic carcinogens and four non-carcinogens on NRK-52E cells using a transcriptomics approach. Toxicology Research, :110-110

McAllister L, Evans A, Hutcheon G, Gaskell E. 2009. Encapsulation of epirubicin for the treatment of cancer JOURNAL OF PHARMACY AND PHARMACOLOGY, 61 :A82-A82 >Link

Bloch K, Evans A, Lock EA. 2009. Developing an in vitro method for assessing the carcinogenic potential of compounds to the kidney. Toxicology, :9-9

McAllister L, Evans A, Hutcheon G, Gaskell E. 2009. Encapsulation of epirubicin for the treatment of cancer. J. Pharm. Pharmacol., Suppl. :A77-A77

Hermitage N, Evans A, Houghton P, Stratford I, Estlin E, Airley R. 2004. Hypoxia-regulated gene expression in rhabdomyosarcoma cell lines BRITISH JOURNAL OF CANCER, British Cancer Research Meeting 2004 91 :S68-S68 >Link

Santos K, Evans A, Kelsey A, Wynn R, Estlin E, Airley R. 2004. Is hypoxia a therapeutic target in haematological malignancies? GLUT-1 and LDH expression in acute lymphoblastic leukaemia BRITISH JOURNAL OF CANCER, British Cancer Research Meeting 2004 91 :S49-S49 >Link

Lunt A, Evans A, Houghton P, Stratford I, Estlin E, Airley R. 2004. The role of MYCN amplification and hypoxia in the expression of facilitative glucose transporters in neuroblastoma cell lines lililinesroblastoma cell lines BRITISH JOURNAL OF CANCER, British Cancer Research Meeting 2004 91 :S48-S48 >Link

Evans A, Hewitt S, Stratford IJ, Airley RE. 2003. Glut-1 as a novel target for anticancer therapy: A compare analysis using the NCI panel of 60 cell lines BRITISH JOURNAL OF CANCER, British Cancer Research Meeting 2003 88 :S12-S12

Segun PA, Ismail F, Ogbole OO, Nahar L, Evans AR, Sarker SD. Antiproliferative activities of Citrus aurantium against breast (MCF7), cervix (HeLa) and urinary bladder (EJ138) carcinoma cells >DOI

Sharma S, Hemers E, Evans A. Investigation into the role of HMGb1 in relation to myofibroblasts and cancer cells exposed to various conditions NCRI Poster Abstracts, National Cancer Research Institute (NCRI) :283-283

Airley R, Evans A, Harris B, Winchester L, Leek R, Harris A. Carbohydrate responce element binding protein (ChREBP) - a new metabolic biomarker in breast cancer? European Jounral of Cancer, 22nd Biennial congress of the European Association for Cancer Research 48 :S80-S80

Evans AR, Alexander D, Burke P, Reed CJ. Toxicity and transfection efficiency: comparison between four commercially available non-viral transfection reagents in a human bronchial epithelial cell line. British Pharmaceutical Conference Abstract Book, :2001

Evans AR, Brittain-Dissont S, Williams KJ, Stratford IJ, Airley RE. The facilitative glucose transporter GLUT-1 as a target for novel anti-cancer agents. Eur. J. Cancer, :2004

Brittain-Dissont SJ, Williams KJ, Sheppard F, Evans A, Carruthers A, Stratford I, Airley R. Role of glucose transporter Glut-1 in tumour growth and response to therapy. Br. J. Cancer, Suppl 1 :2004


Gaskell EE, Evans A, Henney N, Penson P, Elliott PNC, Burrell H, Airley R, Ford W, Lane E, Allison GL. 2013. Therapeutics and Human Physiology Gaskell EE, Rostron C. OUP Oxford. Oxford, UK 9780199655298


Evans AR. 2013. Molecular Cell Biology Gaskell E, Rostron C. Therapeutics and Human Physiology: How drugs work (Intergrated Foundations Of Pharmacy) OUP Oxford 978-0199655298

Engagement & Impact

External collaboration:

Institution: Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain, Collaborator: Dr Jonai Pujol Gimenez & Prof. Maria Lostao

Institution: Department of Pharmacy, Huddersfield University, UK, Collaborator: Dr Rachel Airley

Institution: Tom Connors Cancer Research Unit, University of Bradford, UK., Collaborator: Dr Roger Phillips

Industrial connections:

Company: Quality Control North West (QCNW) associated with the NHS, Position or project: Lead supervisor for 1 MSc students funded by Quality Control North West (QCNW) as part of a larger National study (VEGF in Age-related choroidal Neovascularisation study (IVAN)). 2nd supervisor for 1 MSc student funded by Quality Control North West (QCNW) and the Marie Curie Palliative Care Institute, Liverpool)

Membership of professional bodies:

British Association of Cancer Research (BACR), British Association of Cancer Research (BACR)

Research Grants Awarded:

The School of Pharmacy and Bimolecular Science, The role of HMGb1 in relation to myofibroblasts and cancer cells exposed to various microenvironmental stress conditions, Grant value (£): Approx Value £40,000, Duration of research project: 3 years